Therapeutic | Tesidolumab |
Target | C5 |
Heavy Chain | EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIGPFFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARDTPYFDYWGQGTLVTVSS |
Light Chain | SYELTQPLSVSVALGQTARITCSGDSIPNYYVYWYQQKPGQAPVLVIYDDSNRPSGIPERFSGSNSGNTATLTISRAQAGDEADYYCQSFDSSLNAEVFGGGTKLTVL |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | MorphoSys HuCAL Phage Display;XmAb Engineering Technology |
INN Year Proposed | 2014 |
INN Year Recommended | 2015 |
Companies Involved | MorphoSys, Novartis |
Conditions Approved | na |
Conditions Active | Paroxysmal nocturnal haemoglobinuria |
Conditions Discontinued | Choroiditis, Dry age-related macular degeneration, Panuveitis, Thrombotic microangiopathy, Wet age-related macular degeneration |
Notes |